Clinical trial • Phase I • Oncology

LY3410738 for Advanced hematologic malignancies with IDH1 or IDH2 mutations

Phase I trial of LY3410738 for Advanced hematologic malignancies with IDH1 or IDH2 mutations. 105 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Advanced hematologic malignancies with IDH1 or IDH2 mutations
Trial Stage
Phase I
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
04-09-2024
First CTIS Authorization Date
29-10-2024

Trial design

Phase I trial across 2 sites in France.

Target Sample Size
105

Recruitment

Planned Sample Size
105
Recruitment Window Months
69

Geography

Total Number Of Sites
2
Total Number Of Participants
105

France

Earliest CTIS Part Ii Submission Date
18-09-2024
Latest Decision Or Authorization Date
11-04-2025
Processing Time Days
205
Number Of Sites
2
Number Of Participants
34

Sites

Site Name
Hopital Saint Louis
Department Name
Centre d´Investigation Cliniques
Contact Person Name
Lina Benajiba
Contact Person Email
lina.benajiba@aphp.fr
Site Name
Hospices Civils De Lyon
Department Name
Hématologie
Contact Person Name
Heiblig Mael
Contact Person Email
mael.heiblig@chu-lyon.fr

Sponsor

Primary sponsor

Full Name
Eli Lilly & Co.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
LY3410738
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral

Related trials

Other published trials that may interest you.